Biomarkers /
ERBB4
Overview
Erb-b2 receptor tyrosine kinase 4 (ERBB4) is a gene that encodes a receptor tyrosine kinase in the epidermal growth factor family. Missense mutations, nonsense mutations, silent mutations, and frameshift deletions are observed in cancers such as endometrial cancer, intestinal cancer, and stomach cancer.
ERBB4 is altered in 3.15% of all cancers with lung adenocarcinoma, colon adenocarcinoma, cutaneous melanoma, melanoma, and breast invasive ductal carcinoma having the greatest prevalence of alterations [3].
The most common alterations in ERBB4 are ERBB4 Mutation (2.91%), ERBB4 Loss (0.06%), ERBB4 R711C (0.04%), ERBB4 Amplification (0.04%), and ERBB4 R95C (0.04%) [3].
Clinical Trials
Significance of ERBB4 in Diseases
References
1. Hart R and Prlic A. Universal Transcript Archive Repository. Version uta_20180821. San Francisco CA: Github;2015. https://github.com/biocommons/uta
2. The UniProt Consortium. UniProt: a worldwide hub of protein knowledge. Nucleic Acids Research. 2019;47:D506-D515.
3. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 8. This dataset does not represent the totality of the genetic landscape; see paper for more information.
4. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.